UAE Pulmonary Arterial Hypertension Market Size & Outlook
UAE pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
UAE pulmonary arterial hypertension market highlights
- The UAE pulmonary arterial hypertension market generated a revenue of USD 90.5 million in 2023 and is expected to reach USD 139.4 million by 2030.
- The UAE market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 90.5 million |
| Market revenue in 2030 | USD 139.4 million |
| Growth rate | 6.4% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, UAE accounted for 1.2% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 53.1 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.96% in 2023. Horizon Databook has segmented the UAE pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
UAE pulmonary arterial hypertension market is anticipated to grow at a lucrative growth during the forecast period. The government and NGO encouraged initiatives, in the Middle East are also a sign of the efforts by these countries to reduce the overall PAH burden. In 2018, the Ministry of Health and Prevention issued a Ministerial Resolution that can deliver FastTrack registration of Orphan Drugs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
UAE Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
